These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 19064331)

  • 1. Infliximab for treating axial spondylarthropathy in everyday practice.
    Griffoul I; Giraudeau B; Mulleman D; Benhamou CL; Valat JP; Goupille P
    Joint Bone Spine; 2009 Jan; 76(1):39-43. PubMed ID: 19064331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Six-month response to anti-TNF drugs in axial spondylarthropathy according to the fulfillment or not of New-York criteria for ankylosing spondylitis or French recommendations for anti-TNF use. A "real life" retrospective study on 175 patients.
    Gérard S; le Goff B; Maugars Y; Berthelot JM
    Joint Bone Spine; 2008 Dec; 75(6):680-7. PubMed ID: 18848489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
    McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
    Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with ankylosing spondylitis or psoriatic arthritis: 2007 update.
    Pham T; Fautrel B; Dernis E; Goupille P; Guillemin F; Le Loët X; Ravaud P; Claudepierre P; Miceli-Richard C; de Bandt M; Breban M; Maillefert JF; Masson C; Saraux A; Schaeverbeke T; Wendling D; Mariette X; Combe B;
    Joint Bone Spine; 2007 Dec; 74(6):638-46. PubMed ID: 18065252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of refractory inflammatory monoarthritis in ankylosing spondylitis by intraarticular injection of infliximab.
    Schatteman L; Gyselbrecht L; De Clercq L; Mielants H
    J Rheumatol; 2006 Jan; 33(1):82-5. PubMed ID: 16292792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maintained clinical response of infliximab treatment in ankylosing spondylitis: a 6-year long-term study.
    Saougou I; Markatseli TE; Voulgari PV; Drosos AA
    Joint Bone Spine; 2010 Jul; 77(4):325-9. PubMed ID: 20452801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms.
    Van den Bosch F; Kruithof E; De Vos M; De Keyser F; Mielants H
    Lancet; 2000 Nov; 356(9244):1821-2. PubMed ID: 11117919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).
    van der Heijde D; Dijkmans B; Geusens P; Sieper J; DeWoody K; Williamson P; Braun J;
    Arthritis Rheum; 2005 Feb; 52(2):582-91. PubMed ID: 15692973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistent clinical response of infliximab treatment, over a 4-year period in ankylosing spondylitis.
    Venetsanopoulou AI; Voulgari PV; Alamanos Y; Papadopoulos CG; Markatseli TE; Drosos AA
    Rheumatol Int; 2007 Aug; 27(10):935-9. PubMed ID: 17357804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The inadequate anti-tumour necrosis factor (anti-TNF) therapy in patients with ankylosing spondylitis.
    Borman P; Ayhan F; Ceceli E
    Rheumatol Int; 2010 Nov; 30(12):1689-90. PubMed ID: 20012962
    [No Abstract]   [Full Text] [Related]  

  • 11. Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-term observational study using MRI and conventional radiography.
    Baraliakos X; Heldmann F; Callhoff J; Listing J; Appelboom T; Brandt J; Van den Bosch F; Breban M; Burmester G; Dougados M; Emery P; Gaston H; Grunke M; Van Der Horst-Bruinsma IE; Landewé R; Leirisalo-Repo M; Sieper J; De Vlam K; Pappas D; Kiltz U; Van Der Heijde D; Braun J
    Ann Rheum Dis; 2014 Oct; 73(10):1819-25. PubMed ID: 23852807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years.
    Braun J; Baraliakos X; Brandt J; Listing J; Zink A; Alten R; Burmester G; Gromnica-Ihle E; Kellner H; Schneider M; Sörensen H; Zeidler H; Sieper J
    Rheumatology (Oxford); 2005 May; 44(5):670-6. PubMed ID: 15757965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis.
    Baraliakos X; Haibel H; Listing J; Sieper J; Braun J
    Ann Rheum Dis; 2014 Apr; 73(4):710-5. PubMed ID: 23505240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response.
    Braun J; Baraliakos X; Listing J; Fritz C; Alten R; Burmester G; Krause A; Schewe S; Schneider M; Sörensen H; Zeidler H; Sieper J
    Ann Rheum Dis; 2008 Mar; 67(3):340-5. PubMed ID: 17967831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation.
    de Vries MK; Wolbink GJ; Stapel SO; de Vrieze H; van Denderen JC; Dijkmans BA; Aarden LA; van der Horst-Bruinsma IE
    Ann Rheum Dis; 2007 Sep; 66(9):1252-4. PubMed ID: 17472991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab.
    Baraliakos X; Listing J; Rudwaleit M; Brandt J; Sieper J; Braun J
    Ann Rheum Dis; 2005 Oct; 64(10):1462-6. PubMed ID: 15778240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adiponectin and resistin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy.
    Miranda-Filloy JA; López-Mejias R; Genre F; Carnero-López B; Ochoa R; Diaz de Terán T; González-Juanatey C; Blanco R; Llorca J; González-Gay MA
    Clin Exp Rheumatol; 2013; 31(3):365-71. PubMed ID: 23294554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis.
    Inman RD; Maksymowych WP;
    J Rheumatol; 2010 Jun; 37(6):1203-10. PubMed ID: 20231198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tocilizumab in a patient with ankylosing spondylitis and Crohn's disease refractory to TNF antagonists.
    Brulhart L; Nissen MJ; Chevallier P; Gabay C
    Joint Bone Spine; 2010 Dec; 77(6):625-6. PubMed ID: 20851032
    [No Abstract]   [Full Text] [Related]  

  • 20. High intraindividual week-to-week variability in BASDAI and BASFI values: are several evaluations needed before starting or stopping TNFalpha antagonist therapy for spondyloarthropathies?
    Berthelot JM; Tortellier L; Lavy-Bregeon D; Le Goff B; Maugars Y
    Joint Bone Spine; 2008 Mar; 75(2):167-71. PubMed ID: 18296097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.